Peptides Similar to MET-097i
Compare MET-097i with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semaglutide: High - Both are GLP-1 receptor agonists for obesity treatment
- •Tirzepatide: Moderate - Both target metabolic disease but different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| MET-097i (current) | - | - |
| Semaglutide | High - Both are GLP-1 receptor agonists for obesity treatment | Semaglutide is weekly; MET-097i targets monthly dosing. MET-097i uses HALO platform; semaglutide uses fatty acid acylation. MET-097i is biased; semaglutide is balanced. |
| Tirzepatide | Moderate - Both target metabolic disease but different mechanisms | Tirzepatide is dual GLP-1/GIP agonist (weekly). MET-097i is GLP-1-only (monthly). Tirzepatide achieves greater weight loss. |
| Maritide | Moderate-high - Both are long-acting GLP-1 agonists targeting less frequent dosing | Maritide (Amgen) targets monthly dosing via anti-GLP-1R antibody format. MET-097i uses HALO peptide-oligomer conjugate. |
SemaglutideHigh - Both are GLP-1 receptor agonists for obesity treatment
Differences
Semaglutide is weekly; MET-097i targets monthly dosing. MET-097i uses HALO platform; semaglutide uses fatty acid acylation. MET-097i is biased; semaglutide is balanced.
Advantages
FDA-approved, proven CV benefit, oral formulation available, extensive safety database
Disadvantages
Requires weekly injection; MET-097i's monthly dosing reduces burden
TirzepatideModerate - Both target metabolic disease but different mechanisms
Differences
Tirzepatide is dual GLP-1/GIP agonist (weekly). MET-097i is GLP-1-only (monthly). Tirzepatide achieves greater weight loss.
Advantages
FDA-approved, up to 22.5% weight loss, dual mechanism
Disadvantages
Weekly injection; MET-097i offers monthly convenience
MaritideModerate-high - Both are long-acting GLP-1 agonists targeting less frequent dosing
Differences
Maritide (Amgen) targets monthly dosing via anti-GLP-1R antibody format. MET-097i uses HALO peptide-oligomer conjugate.
Advantages
Also monthly dosing, Amgen development resources
Disadvantages
Antibody-based approach may have different immunogenicity profile
Agents Related to MET-097i#
MET-097i competes in the GLP-1 agonist space with a key differentiator: once-monthly dosing. This positions it against both weekly GLP-1 agents (semaglutide, tirzepatide) and other long-acting candidates (maritide).
| Feature | MET-097i | Semaglutide | Tirzepatide | Maritide |
|---|---|---|---|---|
| Mechanism | GLP-1 (biased) | GLP-1 | GLP-1/GIP | GLP-1 (antibody) |
| Half-life | ~380 hours | ~165 hours | ~116 hours | ~2-4 weeks |
| Dosing | Monthly | Weekly | Weekly | Monthly |
| Weight loss | 12.3% (28 wk) | 14.9% (68 wk) | 15-22.5% | ~14% (52 wk) |
| Technology | HALO conjugate | Acylation | Acylation | Anti-GLP-1R Ab |
| Regulatory | Phase 2b | Approved | Approved | Phase 2 |
Comparison Context#
MET-097i belongs to the Metabolic category of research peptides. Comparing MET-097i with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to MET-097i in mechanism, indication, or therapeutic category:
MET-097i vs Semaglutide#
Similarity: High - Both are GLP-1 receptor agonists for obesity treatment
Key Differences: Semaglutide is weekly; MET-097i targets monthly dosing. MET-097i uses HALO platform; semaglutide uses fatty acid acylation. MET-097i is biased; semaglutide is balanced.
Advantages of Semaglutide: FDA-approved, proven CV benefit, oral formulation available, extensive safety database
Disadvantages of Semaglutide: Requires weekly injection; MET-097i's monthly dosing reduces burden
Researchers choosing between MET-097i and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
MET-097i vs Tirzepatide#
Similarity: Moderate - Both target metabolic disease but different mechanisms
Key Differences: Tirzepatide is dual GLP-1/GIP agonist (weekly). MET-097i is GLP-1-only (monthly). Tirzepatide achieves greater weight loss.
Advantages of Tirzepatide: FDA-approved, up to 22.5% weight loss, dual mechanism
Disadvantages of Tirzepatide: Weekly injection; MET-097i offers monthly convenience
Researchers choosing between MET-097i and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.
MET-097i vs Maritide#
Similarity: Moderate-high - Both are long-acting GLP-1 agonists targeting less frequent dosing
Key Differences: Maritide (Amgen) targets monthly dosing via anti-GLP-1R antibody format. MET-097i uses HALO peptide-oligomer conjugate.
Advantages of Maritide: Also monthly dosing, Amgen development resources
Disadvantages of Maritide: Antibody-based approach may have different immunogenicity profile
Researchers choosing between MET-097i and Maritide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About MET-097i
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer